MedTrace Logo

A Clinical Study of FT1 in Patients With Short Bowel Syndrome

NCT07704047 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-07-15

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if FT1 is safe and works to treat short bowel syndrome (SBS) in adults. It will also learn about the PK/PD profile of FT1.

Researchers will compare FT1 to a placebo (a look-alike substance that contains no drug) to see if FT1 is safe and effective in patients with SBS.

Participants will

* Receive multiple injections of FT1 or placebo according to weight.
* Visit the clinic for assessment.

Conditions

  • Short Bowel Syndrome
  • SBS

Interventions

DRUG

FT1

FT1 treatment, once weekly for 5 weeks

DRUG

Placebo

Placebo, once weekly for 5 weeks

Sponsors & Collaborators

  • Chongqing Peg-Bio Biopharm Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-30
Primary Completion
2027-04-15
Completion
2027-04-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07704047 on ClinicalTrials.gov